










































Pharmacogenetics and ethnically targeted therapies
Citation for published version:
Rahemtulla, T & Bhopal, R 2005, 'Pharmacogenetics and ethnically targeted therapies' BMJ, vol. 330, no.
7499, pp. 1036-7. DOI: 10.1136/bmj.330.7499.1036
Digital Object Identifier (DOI):
10.1136/bmj.330.7499.1036
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
secondary prevention of coronary heart disease. In
terms of primary prevention, development and testing
of combination pills aimed at reducing more than one
risk factor seems entirely logical, particularly in the
context of assessment of global cardiovascular risk.
Funding bodies and the NHS need to support the nec-
essary trials and cost effectiveness studies to further
examine the polypill strategy in comparison with non-
pharmacological alternatives.
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Pharmacogenetics and ethnically targeted therapies
New drug BiDil marks the return of biology to the debate about race and ethnicity
In modern conceptions of race and ethnicity,biology has been relegated to a minor underlyingfactor.1 Instead, these concepts have been cast as
largely social constructions.2 For example, race
traditionally distinguishes between groups according
to a mixture of physical characteristics (including skin
colour), which reflect ancestry and hence biology. A
modern conception of race would place the emphasis
on a common social and political heritage. Similarly,
ethnicity puts emphasis on distinguishing between
groups by using a mixture of cultural factors, including
language and religion.2 Recent developments in phar-
macogenetics, however, renew the historical emphasis
on biology in concepts of race and ethnicity.
Pharmacogeneticists examine whether different
responses to drug treatment may be attributable to
genetic differences. They are focusing on race and eth-
nicity as a means to this end. A recent international
conference, the 8th world congress on clinical
pharmacology and therapeutics, in Brisbane, Australia,
had an afternoon on ethnopharmacology, showing
how seriously this new subject is being taken.3
In the middle of this resurgence of the role of biol-
ogy in concepts of race and ethnicity comes BiDil, a
new drug treatment for heart failure tested solely in
one particular racial group. In 2001 NitroMed began
the African-American heart failure trial (A-HeFT), the
first heart failure trial conducted exclusively in
African-American patients, claiming that “observed
racial disparities in mortality and therapeutic response
rates in Black heart failure patients may be due in part
to ethnic differences in the underlying pathophysiol-
ogy of heart failure.”4 5 The study found that BiDil (a
fixed dose of isosorbide dinitrate and hydralazine,
designed to restore low or depleted nitric oxide
concentrations to the blood) combined with standard
therapy for heart failure reduced mortality by 43%
among black patients.5 Hailed by the media as the first
ethnic drug, BiDil is reported to be on the way to
becoming the first drug approved by the US Food and
Drug Administration to treat heart failure in
African-American patients only.6
The major implication of BiDil is that differential
responses to treatment between racial groups, defined
by using ostensibly social categories (here, patients self
reported to be African-Americans), are attributed
primarily to genetic differences. If this is shown to be
true it will undermine a postwar consensus emphasis-
ing the social construction of race and ethnicity.
Largely social categories of race and ethnicity may be
useful indicators of genetic variations because they are
at least partly based on biological characteristics. If
everyone were the same physically—skin colour and so
on—racial and ethnic categories would not exist. This
raises fundamental and controversial questions. Do
important genetic differences exist between ethnic and
racial groups as defined by current classifications? If
they do, how good are current racial labels as an indi-
cator of these genetic differences? Should such classifi-
cations be used in this way? If so, will race science see a
resurgence?1
Many researchers and policy makers argue against
the use of racial or ethnic categories in medicine,
saying that classifying people according to race and
ethnicity reinforces existing social divisions in society
or leads to discriminatory practices.7 Others cite
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research showing that genetic differences are greater
within socially defined racial groups than between
groups.8 The relation between features that tradition-
ally define race and contribute to ethnicity, such as skin
colour, and genetic differences has been found to be
inconsistent.9 In addition, by focusing on biological
factors as the explanation for differences in response
to drugs, researchers risk ignoring other possible envi-
ronmental, psychosocial, and economic factors, and
lifestyle factors such as diet, that are important in pro-
ducing illness.7 If important genetic variations exist
between currently defined racial and ethnic groups,
drug treatments may be tailored for greater effect.
In a review of the research on the effects of
cardiovascular therapies carried out by Taylor and Ellis,10
the evidence for ethnic variations in response to such
drugs seems modest—a conclusion we reached in our
own review in July 2004 and presented at the conference
in Brisbane.3 Diuretics were found to be beneficial for
both black and white patients with heart failure. Black
patients were found to respond equally well to
angiotensin receptor blockers, spironolactone, digoxin,
and carvedilol (-adrenoceptor antagonists). Compared
with white patients, black patients were found to
respond less well to angiotensin converting enzyme
inhibitors (enalapril),10 though this conclusion has been
contested. Yu et al showed that Chinese patients
required lower dosages of heparin and warfarin than
those usually recommended for white patients.11 12
The new genetics has reopened the debate on the
biological basis of race and ethnicity. Pharmacogenet-
ics is growing fast, and it will lead to a more refined
understanding of ethnic and racial differences in drug
response.Many claims and counterclaims will be made.
Doctors need to take an open minded but critical
stance. A historical perspective is likely to be helpful—
claims of a biological basis to racial or ethnic variations
in health and disease, including therapeutics, have
proved to be overstated.1
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Prevalence of asthma
Is no longer increasing in some countries, but the reasons for this are unclear
Abroad consensus exists that in most Westerncountries the prevalence of asthma increasedover the last four decades of the 20th century.
This is based largely on repeat studies of school
age children. Evidence is emerging that in recent years
this trend has flattened or fallen in some countries. For
example, as part of the UK arm of the international
study of asthma and allergies in childhood (ISAAC),
repeat studies found that self reported symptoms of
asthma in 13-14 year old children had fallen by about
20% in the United Kingdom between 1995 and 2002.1
This trend was also observed in the health survey for
England between 1996 and 2001.2 Over the same
period a similar fall in symptoms of asthma in 6-7 year
old children reported by parents was seen in
Melbourne.3 On the other hand, the only available
repeat survey of preschool children noted a major
increase in prevalence between 1990 and 1998.4
A global picture of recent trends in children will
soon be provided by the results of ISAAC phase 3,
which has obtained trends in prevalence between
1995 and 2002 in more than 100 centres in 58
countries.5 Little information exists about long term
trends in adults, but recent trends in the UK seem to
be flat.2 6
These data are limited by the lack of an objective
measure of asthma in large populations and the
reliance on surveys to elicit symptoms of wheezy
breathlessness, which are likely to represent a
heterogeneous group of disorders.7 Questions about
lifetime prevalence are subject to serious recall bias,
and the usual compromise is to rely on the 12 month
period of prevalence in an attempt to capture the
intermittent nature of symptoms experienced by most
people with asthma, while limiting the recall entailed
and avoiding problems with labelling. Trends in the
cultural perception and naming of symptoms might
explain the trends observed in prevalence studies,8 and
while it remains true that without objective measures
we cannot be certain how much is real and how much
is artefact it seems unlikely that artefact would
completely explain the observed trends.
If the trend is indeed flattening or decreasing,
might it be explained by trends in health care? The use
Editorials
BMJ 2005;330:1037–8
1037BMJ VOLUME 330 7 MAY 2005 bmj.com
